TL;DR
- 1.GHSR fires at roughly 50% of maximum capacity with no peptide present. This tonic background signal drives the chronic GH secretion that accumulates into IGF-1 between injections. Loss-of-function variants destroy this baseline without necessarily blocking your injection response at all.
- 2.A 2025 JCEM study (Punt et al.) of 26 heterozygous GHSR variant carriers found mean IGF-1 of negative 1.6 SDS despite normal acute GH peaks of 10.8 to 32.7 mcg/L on stimulation testing. The injection fires. The chronic signal does not exist.
- 3.There are at least three distinct GHSR failure modes: constitutive activity loss (tonic signal silenced, injection may still work), binding failure (injection also fails), and surface expression loss (everything is reduced proportionally). A stimulation test cannot tell them apart.
- 4.No dose of ipamorelin, MK-677, or any ghrelin mimetic can compensate for absent constitutive activity. The receptor needs to fire on its own between doses. When it cannot, you are filling a tank with a hole in the bottom.
- 5.The fastest diagnostic test is a CJC-1295 switch. CJC-1295 does not use GHSR at all. If your IGF-1 responds to CJC-1295 but not to ipamorelin, the bottleneck is at GHSR, not downstream.
Your ipamorelin injection is working. The 45-minute post-injection test shows the GH spike right where it should be. But your IGF-1 after eight weeks on the same protocol is unchanged. Forums have five explanations ready: bad product, wrong timing, carbs before the shot, high body fat, too much stress. Not one of them mentions the GHSR gene. That is where the actual answer often lives.
GHSR (the ghrelin receptor) runs at roughly 50% of its maximum firing capacity with no peptide present. This tonic background signal drives the chronic GH secretion that accumulates into IGF-1 between injections. Loss-of-function variants selectively destroy this background hum without necessarily blocking the injection response at all.
The GHSR non-responder problem is not about your peptide failing to hit the receptor. It is about what the receptor does between doses. Understanding the difference changes how you interpret flat IGF-1 results and what you do next.
Plain English: Think of GHSR as a pump with two settings: a background hum that runs all day at half speed, and a full burst when ipamorelin arrives. Loss-of-function variants turn off the background hum while leaving the burst mostly intact. You get the spike at injection time. You lose the 23 hours of tonic signal that actually builds IGF-1. Your protocol looks fine in the short window you test. The 24-hour picture is missing half the signal.
Your injection fires. So why is your IGF-1 still flat?
This is the finding that makes GHSR non-response so easy to miss. A 2025 study in the Journal of Clinical Endocrinology and Metabolism (Punt et al.) followed 26 patients carrying heterozygous GHSR loss-of-function variants. All 26 showed completely normal peak GH on stimulation testing, with values ranging from 10.8 to 32.7 mcg/L. Clinically, every one of them would pass a standard GH stimulation test with no flags raised.
Their chronic IGF-1 told a different story. Mean IGF-1 across the cohort sat at negative 1.6 standard deviations below normal. Mean height was negative 2.8 standard deviations. These patients were short, chronically IGF-1 suppressed, and completely normal on acute GH stimulation.
Pantel and colleagues identified the underlying mechanism in a 2006 paper in the Journal of Clinical Investigation. The receptor fires when provoked by an injection or stimulation test. It does not fire on its own between provocations. They called this "neurosecretory dysfunction": normal stimulated GH with impaired spontaneous, pulsatile release and chronically reduced IGF-1.
"Loss of constitutive activity of the growth hormone secretagogue receptor causes a familial short stature syndrome with normal stimulated GH secretion but impaired spontaneous pulsatile GH release and reduced IGF-1."
Pantel et al., Journal of Clinical Investigation, 2006
For peptide users, this maps precisely onto the forum report you have seen or experienced: the GH test at 45 minutes post-injection looks fine. IGF-1 at week 8 is flat. Dose escalation does not help. The problem is not the injection. The problem is the 23 hours between injections.
Mean IGF-1 in 26 heterozygous GHSR variant carriers despite normal stimulated peak GH (10.8 to 32.7 mcg/L on stimulation testing). Chronically suppressed IGF-1 with a working injection response is the diagnostic fingerprint of GHSR constitutive activity loss. Source: Punt et al., JCEM, 2025.
The 50% of your GH output that has nothing to do with your injections
GHSR is unusual among receptors. Most receptors sit idle until their ligand arrives. GHSR fires at roughly 50% of maximum capacity with no ligand present at all. This baseline self-activation is constitutive activity, and it drives the tonic, non-pulsatile GH secretion that runs continuously between your injection windows.
The significance for peptide users is direct. When you inject ipamorelin, you are triggering the ligand-stimulated arm of the receptor: the burst that releases a GH pulse from your pituitary. That burst clears from your blood in roughly 15 to 20 minutes. But your pituitary is also secreting GH at a low tonic level for the remaining 23 hours of the day, driven by the receptor's constitutive activity. That tonic signal is what accumulates into measurable IGF-1 over days and weeks.
Loss-of-function variants in GHSR can selectively disable the constitutive activity while leaving the injection-stimulated response partially or fully intact. Pantel et al. documented the A204E variant (p.Ala204Glu) doing exactly this: zero detectable constitutive basal signaling with a preserved ghrelin-triggered response. The injection still fires. The background signal that should run all day is silent.
Not all GHSR variants work the same way: the three failure modes
A 2007 pharmacology paper from Liu and colleagues at Tufts (published in the Journal of Pharmacology and Experimental Therapeutics) tested four human GHSR missense variants directly at the receptor level. The results show that "GHSR non-responder" is not one phenomenon. It is at least three distinct pharmacological failure modes at different steps.
Constitutive activity loss (A204E, V160M)
The receptor's background hum is silenced or reduced. The injection-stimulated GH response may be partially preserved. Your 45-minute post-injection test can look fine while chronic IGF-1 stays low. No dose of ipamorelin or MK-677 can compensate for the missing tonic signal between doses.
Binding failure (I134T)
The variant is completely unresponsive to ghrelin in pharmacological testing (Liu et al., 2007). This class blocks the injection response too, not just the tonic signal. Ipamorelin, MK-677, GHRP-2, and hexarelin all bind through the same ghrelin-mimetic pathway and hit the same wall.
Surface expression loss (F279L and others)
Reduced total receptor density at the cell surface. Every signal type is blunted proportionally, both tonic and pulsatile. Response is reduced rather than absent. This class produces a dose-response curve that is flatter than expected, not a hard floor of zero.
All four variants tested by Liu et al. showed reduced receptor surface expression compared to wild-type GHSR. The critical implication: a standard GH stimulation test cannot distinguish between these three failure modes. The only way to identify GHSR variant status is genetic analysis, not provocative endocrine testing.
What the largest GHSR variant study actually found
The Punt et al. 2025 study in JCEM is the most comprehensive clinical dataset on GHSR loss-of-function to date. Across 26 patients with heterozygous GHSR variants, the researchers identified 10 distinct variants, 6 of which had never been described before. These are not a fixed catalog. Novel variants are being identified across European, African, South American, and East Asian populations, suggesting the problem is far more widespread than the small published literature implies.
Incomplete penetrance matters here. Not all carriers within the same family express the same clinical picture. The Punt cohort ranged from negative 1.1 to negative 3.7 standard deviations in height, all carrying the same class of variant. Your genetic result tells you where your risk sits, not exactly where your result will land.
No published trial has tested ipamorelin or MK-677 in confirmed GHSR loss-of-function carriers. The inference from in vitro pharmacology (Liu 2007) and clinical endocrinology (Pantel 2006, Punt 2025) is mechanistically well-grounded. But the specific secretagogue peptide response in variant carriers has not been directly measured in a controlled trial. You should factor in both the mechanistic plausibility and the evidentiary gap.
How to tell if GHSR is your bottleneck
The fastest practical screen uses tools most peptide users already have access to. The table below shows what each test can and cannot tell you.
| Test | What it shows | GHSR LOF pattern |
|---|---|---|
| Home GH test 45 min post-injection | Acute pulsatile response to ipamorelin | Often normal in constitutive-loss variants (injection still fires) |
| Fasting IGF-1 at week 8 | Cumulative chronic GH axis output | Flat or below baseline despite a normal injection response |
| Switch to CJC-1295 alone for 4 weeks | GHRH pathway (does not bind GHSR) | IGF-1 responds to GHRH pathway even when GHSR is the bottleneck |
| DNA panel with GHSR genotyping | Variant status directly | Definitive identification; not covered by standard 23andMe panels |
The CJC-1295 switch is the most underused diagnostic tool for non-responders. CJC-1295 binds GHRH receptors, not GHSR. It works through a different receptor system to amplify GH pulse amplitude. If you switch from ipamorelin (GHSR-dependent) to CJC-1295 plus ipamorelin and your IGF-1 moves on CJC-1295 alone but not on ipamorelin alone, that result points directly at a GHSR bottleneck. The protocol comparison article at ipamorelin vs CJC-1295 covers how to structure that test correctly.
If both ipamorelin and CJC-1295 produce no IGF-1 response, the bottleneck is more likely downstream. The article on IGF-1 receptor genetics and growth peptide response covers the downstream steps in the GH axis in detail. The GHR Exon 3 article explains the receptor efficiency variant that affects roughly half the population and produces a different (and more recoverable) failure pattern than GHSR loss-of-function.
Does MK-677 help if you have GHSR loss-of-function?
MK-677 (ibutamoren) is a small-molecule GHSR agonist that works through the same ghrelin-mimetic binding pathway as ipamorelin and GHRP-2. If your GHSR variant blocks ghrelin-mimetic binding (the I134T failure mode), MK-677 hits the same wall that ipamorelin does. A different molecule, the same receptor problem.
The constitutive-activity-loss variants are a different case. MK-677 has a 24-hour half-life versus ipamorelin's roughly 2-hour window. At sufficient concentrations, sustained GHSR agonism might partially compensate for absent constitutive activity by keeping the receptor stimulated for more of the day. This is mechanistically plausible. No clinical data exists in GHSR variant carriers specifically. Do not design your protocol around a theoretical advantage that has not been measured.
WADA bans MK-677 alongside ipamorelin, GHRP-2, hexarelin, and all ghrelin-mimetics under S2 on the 2026 Prohibited List. For competitive athletes, the WADA status applies regardless of non-responder genetics. For ipamorelin specifically, it returned to legal 503A compounding in the US in April 2026 after an HHS-directed regulatory reversal, with formal PCAC review scheduled for late July 2026.
Verdict: If your ipamorelin injection visibly fires on a 45-minute GH test but your IGF-1 stays flat after 8 weeks on protocol, GHSR constitutive activity loss is your most likely upstream explanation. The 2025 JCEM data (Punt et al.) confirms the pattern is real and clinically documented: heterozygous GHSR variant carriers average negative 1.6 SDS IGF-1 despite normal stimulated GH peaks. No dose escalation fixes a tonic signaling gap that the receptor needs to maintain on its own between injections. Test your GHRH pathway with CJC-1295 to isolate the bottleneck, then get the genetic data that tells you which receptor system to build around. Upload your raw genetic data at PeptidesDNA or order a saliva kit to find out where your GH axis actually sits.
Your DNA shapes how you respond to every peptide in this report.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
Why is my ipamorelin not working?
The most commonly missed cause is GHSR loss-of-function: a genetic variant that silences the receptor's tonic background signal between injections without blocking the injection response itself. Your GH spike at 45 minutes may look normal while chronic IGF-1 stays flat after weeks of protocol. Other causes include GHR Exon 3 fl/fl genotype (reduced downstream receptor sensitivity), IGFBP-3 variants, or protocol timing errors. A CJC-1295 switch test and a baseline-to-week-8 IGF-1 comparison help isolate which step is failing.
What is GHSR constitutive activity and why does it matter for IGF-1?
GHSR fires at roughly 50% of its maximum capacity even without ghrelin or any synthetic agonist present. This self-activation drives low-level tonic GH secretion continuously throughout the day, not just at injection time. Loss-of-function variants that specifically destroy this constitutive activity remove the chronic baseline signal without blocking the acute injection response. The result is a normal-looking 45-minute GH spike with chronically suppressed IGF-1 across the day.
Can you test for GHSR genetic variants?
Standard consumer panels like 23andMe do not genotype GHSR loss-of-function variants. The PeptidesDNA report includes GHSR variant analysis with raw genetic data uploads or saliva kit orders. Clinical pharmacogenomics labs and some academic medical centers can run targeted GHSR sequencing on request. Standard endocrine stimulation tests (arginine, ITT, OGTT suppression) cannot identify GHSR variant status because heterozygous carriers pass them with normal peak GH values.
Is MK-677 a solution for GHSR non-responders?
MK-677 binds the same GHSR receptor as ipamorelin and faces the same genetic bottleneck for binding-site failure variants (like I134T). For constitutive-activity-loss variants (like A204E), MK-677's 24-hour half-life may provide more sustained receptor occupancy than short-acting peptides, potentially partially compensating for the absent tonic signal. No clinical trial has tested this in confirmed GHSR variant carriers. It is mechanistically plausible but not proven.
How do GHSR non-responders differ from GHR Exon 3 fl/fl users?
These are two separate genes at two different steps in the same chain. GHSR is where ipamorelin binds to trigger GH release from the pituitary. GHR (growth hormone receptor) is where that released GH lands in peripheral tissue to produce IGF-1. GHSR loss-of-function prevents the GH release signal from running properly between doses. GHR Exon 3 fl/fl means GH release is normal but the downstream conversion to IGF-1 is less efficient per pulse. You can carry both problems independently of each other.
What is the fastest way to check if GHSR is my bottleneck?
Run a home GH test 45 minutes after your ipamorelin injection. A normal GH spike means the injection is firing and the GHSR binding response is working. Then check fasting IGF-1 at baseline and again at week 8. Flat IGF-1 with a working injection response points at a tonic signal or downstream problem. Switching to CJC-1295 alone for 4 weeks tests the GHRH pathway, which does not use GHSR at all. If IGF-1 responds to CJC-1295 but not to ipamorelin, GHSR is your bottleneck.
Why did a growth hormone stimulation test say I was normal if I have a GHSR variant?
Stimulation tests measure the acute pulsatile GH response to a pharmacological trigger. They are designed to detect complete GH deficiency, not constitutive receptor dysfunction. GHSR constitutive activity loss impairs the tonic, spontaneous GH release between stimulation events, not the stimulated peak itself. The 26 heterozygous variant carriers in the 2025 JCEM study all passed stimulation testing with peak GH between 10.8 and 32.7 mcg/L. Stimulation tests are the wrong test for this specific bottleneck.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.